|
|
|
|
|
Received: 02 February 2019
|
|
|
|
|
|
| [1] |
Bouvier N M, Palese P. The biology of influenza viruses [J]. Vaccine, 2008, 26(s4): D49-D53.
|
| [2] |
Wang Z, Wan Y, Qiu C, et al. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8+ T cells [J]. Nat Commun, 2015, 6(5):6833.
|
| [3] |
龚震宇, 龚训良. 全球流感活动概况(2016年10月至2017年10月)[J]. 疾病监测, 2018, 33(3): 90-94.
|
| [4] |
Krammer F, Smith G J D, Fouchier R A M, et al. Influenza[J]. Nat Rev Dis Primers, 2018, 4(6):3.
|
| [5] |
Moasser E, Moasser A, Zaraket H. Incidence of antiviral drug resistance markers among human influenza A viruses in the Eastern Mediterranean Region, 2005-2016[J]. Infect Genet Evol, 2019, 67(1): 60-66.
|
| [6] |
国家卫生健康委办公厅, 国家中医药局办公室. 流行性感冒诊疗方案(2018年版修订版)[EB/OL]. (2018-11-20).[2019-02-03]. http://www.moh.gov.cn/yzygj/s7653/201811/ddcb7962b5bc40fa8021009b8f 72e8a7.shtml.
|
| [7] |
Yang J, Liu S, Du L, et al. A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action[J]. Rev Med Virol, 2016, 26(4):242-250.
|
| [8] |
Colman P, Varghese J, Laver W. Structure of the catalytic and antigenic sites in influenza virus neuraminidase[J]. Nature, 1983, 303(5912): 41-44.
|
| [9] |
Russell R J, Haire L F, Stevens D J, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design [J]. Nature, 2006, 443(7107):45-49.
|
| [10] |
Govorkova E A, Leneva I A, Goloubeva O G, et al. Comparison of efcacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian in uenza viruses[J]. Antimicrob Agents Chemother, 2001, 45(10):2723-2732.
|
| [11] |
Ikematsu H, Kawai N, Iwaki N, et al. Invitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2016-17 season: Comparison with the 2010-11 to 2015-16 seasons [J]. J Infect Chemother, 2018, 24(9):707-712.
|
| [12] |
Alame M M, Elie M, Hassan Z. Peramivir: A novel intravenous neuraminidase inhibitor for treatment of acute influenza infections[J]. Front Microbiol, 2016, 7:1-14.
|
| [13] |
Lee N, Hurt A C. Neuraminidase inhibitor resistance in influenza: a clinical perspective [J]. Curr Opin Infect Dis, 2018, 31(6): 520-526.
|
| [14] |
Mckimm-Breschkin J L. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance[J]. Influenza Other Respir Viruses, 2013, 7(s1):25-36.
|
| [15] |
Govorkova E A, Mccullers J A. Therapeutics against influenza[J]. Curr Top Microbiol Immunol, 2011, 370:273-300.
|
| [16] |
Ison M G. Antivirals and resistance: influenza virus[J]. Curr Opin Virol, 2011, 1(6): 563-573.
|
| [17] |
禤肇泉, 谭力雄. 磷酸奥司他韦治疗流感样症状患者的疗效观察[J]. 海峡药学, 2016, 28(5):109-110.
|
| [18] |
周招鹏, 胡梦泽. 磷酸奥司他韦颗粒联合单磷酸阿糖腺苷治疗小儿手足口病的疗效观察[J]. 现代药物与临床, 2016, 31(9):1427-1429.
|
| [19] |
王晓红, 林 燕, 胡 丹, 等. 奥司他韦联合炎琥宁在小儿病毒性肺炎中的应用[J]. 河北医学, 2017, 23(4):535-539.
|
| [20] |
Moscona A. Neuraminidase inhibitors for influenza[J]. New Engl J Med, 2005, 353(13):1363-1373.
|
| [21] |
L’Huillier A G, Ing L K, Crisinel P A, et al. ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia[J]. Pharmacogenomics, 2011, 12(10):1493-1501.
|
| [22] |
Nakamura Y, Sugawara T, Ohkusa Y, et al. Life-threatening abnormal behavior incidence in 10-19 year old patients administered neuraminidase inhibitors [J]. PLoS One, 2015, 10(7):e0129712.
|
| [23] |
Zaraket H, Saito R. Japanese surveillance systems and treatment for influenza[J]. Curr Treat Options Infect Dis, 2016, 8(4):311-328.
|
| [24] |
赵冬梅, 潘晓娇. 抗流感药物磷酸奥司他韦的研究进展[J]. 医药前沿, 2017, 7(5):5-6.
|
| [25] |
Beau A B, Hurault-Delarue C, Vial T, et al. Safety of oseltamivir during pregnancy: a comparative study using the EFEMERIS database[J]. BJOG-Int J Obstet Gy, 2014, 121(7):895-900.
|
| [26] |
Graner S, Svensson T, Beau A B, et al. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study [J]. BMJ, 2017, 356:j629.
|
| [27] |
Shi D, Yang J, Yang D, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel[J]. J Pharmacol Exp Ther, 2006, 319(3):1477-1484.
|
| [28] |
卞家蓉, 聂 蔚, 叶 俊, 等. 扎那米韦吸入粉雾剂治疗流感及流感样患者的随机双盲对照多中心研究[J]. 中国新药与临床杂志, 2013, 32(9):696-700.
|
| [29] |
Ison M G. Clinical use of approved in uenza antivirals: therapy and prophylaxis[J]. Influenza Other Respir Viruses, 2013, 7(s1):7-13.
|
| [30] |
Ison M G, Hui D S, Clezy K, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults[J]. Antivir Ther, 2013, 18(5):651-661.
|
|
|
2019, Vol. 30 
